Upadacitimab (Upadvex)
Product detail for Upadacitimab, INN: upadacitimab. Therapeutic area: Immunology. This record shows all linked substances, markets, applications, presentations, and labeling artefacts.
Product ID
PROD-023
INN
upadacitimab
Therapeutic Area
Immunology
Status
Pending
Owner
James O'Brien
Created
2022-08-25
Last Updated
2023-04-30
Markets
11
Presentations
| Form | Strength | Route |
|---|---|---|
| Ophthalmic solution | 25 mg | Topical |
| Transdermal patch | 1 mg/mL | Inhalation |
| Oral solution | 0.5 mg | Intravitreal |
| Film-coated tablet | 5 mg | Oral |
Active Substances
| ID | Name | INN | CAS | Type | Status |
|---|---|---|---|---|---|
| SUB-020 | Erenumabix | erenumabix | 80035-23-4 | biologic | Active |
| SUB-024 | Semaglutidex | semaglutidex | 51393-36-2 | small-molecule | Active |
Applications (3)
| Application # | Market | Procedure Type | Status | Owner | Submitted |
|---|---|---|---|---|---|
| PMDA-2022-0023 | South Africa | Lifecycle Extension | In Progress | Lieselotte van der Berg | 2024-06-19 |
| CDSCO-2022-0053 | South Africa | Type II Variation | Overdue | Sarah Chen | 2023-01-28 |
| PMDA-2022-0083 | South Africa | Type II Variation | Blocked | Sarah Chen | 2023-04-22 |
Markets (11)